Table 2.
Antigen | Epitope | MHC | Clone | Indication | Affinity 1 | Selection method | References |
---|---|---|---|---|---|---|---|
2W | EAWGALANWAVDSA | I-Ab | W6 | Infection | 3.4 nM | Hybridoma | [78] |
Eα | ASFEAQGALANIAVDKA | I-Ab | Y-Ae | Self-peptide | 0.48 nM | Hybridoma | [79] |
LACK | ICFSPSLEHPIVVSGSWD | I-Ad | 2C44 | Infection | ND | Hybridoma | [80] |
insulin | HLVERLYLVCGEEG | I-Ag7 | mAb287 | Autoimmunity | 130 nM | Hybridoma | [81] |
p63 | RTRPLWVRME | I-Ag7 | FS1 | Autoimmunity | 0.02 nM | Hybridoma | [78] |
HEL | NTDGSTDYGILQINSR | I-Ak | B6Ge1 | Model antigen | ND | Hybridoma | [82] |
HEL | KGTDVQAWIRGCRL | I-Ak | D8H21 | Model antigen | ND | Hybridoma | [82] |
HEL | DGSTDYGILQINSRW | I-Ak | Aw3.18 | Model antigen | 12.4 nM | Hybridoma | [83] |
MBP | VHFFKNIVTPRTP | I-As | B-7-1, B-18-7, C34-72 | Autoimmunity | ND | Hybridoma | [84] |
MCC | IAYLKQATK | I-Ek | D4,G32,G35 | Model antigen | 700 nM | Hybridoma | [85] |
HLA-A2 | SDWRFLRGYHQYA | HLA-DR1 | UL-5A1 | Self-peptide | ND | Hybridoma | [86] |
MBP | ENPVVHFFKNIVTPR | HLA-DR2b | MK16 | Autoimmunity | ND | Immunization/phage | [87] |
MOG | MEVGWYRPPFSRVVHLYRNGK | HLA-DR2b | 2E4, 1F11, 3A3, 3H5, 2C3 | Autoimmunity | 30–150 nM | Phage | [88] |
GAD65 | NFFRMVISNPAAT | HLA-DR4.1 | G1H12, G3H8, D2 | Autoimmunity | 64 nM, 104 nM | Phage | [89] |
HC gp-39 | RSFTLASSETGVG | HLA-DR4.1 | 12A | Autoimmunity | ND | Hybridoma | [90] |
Gluten | QLQPFPQPELPY | HLA-DQ2.5 | 106, 107 2 | Autoimmunity | 70 nM, 100 nM | Phage | [91] |
In case of multiple candidate mAbs, the lead candidates are described in the Table. NA; not available. ND; not determined. 1 Affinity values determined by 1:1 binding using surface plasmon resonance or bio-layer interferometry. 2 Docking model of Fv onto pMHC.